UCB: BarCap still underweight, but ups target
(CercleFinance.com) - Barclays Capital (BarCap) maintains its "underweight" rating on UCB, but has raised its target price to 61.
5 euros, following its competitor argenx's presentation of phase 2 data in primary immune thrombocytopenia.
While Argenx's efficacy may at first seem superior at this stage, BarCap has raised its peak sales forecast for UCB's rozimab by 20% after a more detailed analysis of this monoclonal antibody.
However, the broker prefers to maintain its "underweight" rating on the stock of the Belgian pharmaceutical company, as rozimab's longer-term upside potential is tempered by concerns about UCB's core business.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
5 euros, following its competitor argenx's presentation of phase 2 data in primary immune thrombocytopenia.
While Argenx's efficacy may at first seem superior at this stage, BarCap has raised its peak sales forecast for UCB's rozimab by 20% after a more detailed analysis of this monoclonal antibody.
However, the broker prefers to maintain its "underweight" rating on the stock of the Belgian pharmaceutical company, as rozimab's longer-term upside potential is tempered by concerns about UCB's core business.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.